Sabrina Dunbar
Investor Relations
Replay available
GeneDx Holdings Corp. (NASDAQ: WGS) Q3 2025 earnings conference call, held 2025-10-28. Replay captured from the company's public earnings webcast.

Investor Relations
President and Chief Executive Officer
Chief Financial Officer
Chief Operations Officer
Analyst, Guggenheim
Analyst, TD Cowen
Analyst, BTIG
Analyst, Jefferies
Analyst, Kenna Court
Analyst, Freedom Capital Markets
Analyst, Piper Center
Analyst, Craig-Hallum Capital Group
Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Sabrina Dunbar, Investor Relations. Please go ahead. Thank you, Operator, and thank you to everyone for joining us today. On the call, we have Catherine Stulen, President and Chief Executive Officer, Brian DeTero, Chief Operations Officer, and Kevin Feeley, Chief Financial Officer. Earlier today, GDX released financial results for the third quarter and is September 30, 2025. Before we begin, please take note of our cautionary statements. We may make forward-looking statements on today's call, including about our business plans, updated 2025 guidance, and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, October 28th, and we are under no obligation to update. When discussing our results, we refer to non-GAAP measures, which include certain items from reported results. Please refer to our third quarter 2025 earnings release and slides available at ir.gndx.com for definitions and reconciliations of non-GAAP measures. and additional information regarding our results, including a discussion of factors that could cause actual results to materially differ from forward-looking statements. And with that, I'll turn the call over to Katherine. Thank you, Sabrin...